Anti-PKA R2/PKR2 (phospho S99) antibody [E151]
- RabMAb
- Recombinant
- What is this?
4
(1 Review)
|
(52 Publications)
Rabbit Recombinant Monoclonal PKA R2/PKR2 phospho S99 antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Mouse, Rat, Pig, Human samples. Cited in 52 publications.
View Alternative Names
PKR2, PRKAR2, PRKAR2A, cAMP-dependent protein kinase type II-alpha regulatory subunit
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (AB32390)
ab32390, at a 1/250 dilution, staining (A) untreated (B) Phosphatase treated lymph node metastatic by immunohistochemistry, Paraffin embedded human tissue
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (AB32390)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human kidney without Lambda Protein Phosphatase treatment (image A) and treated with Lambda Protein Phosphatase (image B). tissue sections labeling PKA R2/PKR2 with purified ab32390 at 1 : 500 dilution (0.75 μg/ml). Heat mediated antigen retrieval was performed Perform heat mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use)was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (AB32390)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Rat kidney without Lambda Protein Phosphatase treatment (image A) and treated with Lambda Protein Phosphatase (image B). tissue sections labeling PKA R2/PKR2 with purified ab32390 at 1 : 500 dilution (0.75 μg/ml). Heat mediated antigen retrieval was performed Perform heat mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use)was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
- WB
Lab
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (AB32390)
Blocking and dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (ab32390) at 1/10000 dilution
Lane 1:
Untreated K562 whole cell lysate at 10 µg
Lane 2:
K562 whole cell lysate - treated with alkaline phosphatase at 10 µg
Secondary
All lanes:
Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution
Predicted band size: 45 kDa
Observed band size: 51 kDa
false
Exposure time: 3min
- WB
Lab
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (AB32390)
All lanes:
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (ab32390) at 1/1000 dilution
Lane 1:
HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysates at 15 µg
Lane 2:
HeLa (Human cervix adenocarcinoma epithelial cell) were starved for 3 hours and then treated with 100 nM Calyculin A for 30 minutes at 15 µg
Lane 3:
HeLa (Human cervix adenocarcinoma epithelial cell) treated with 100 nM Calyculin A for 30 minutes. Then the membrane was incubated with phosphatase at 15 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 45 kDa
Observed band size: 51 kDa
false
- WB
Lab
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (AB32390)
Blocking and dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (ab32390) at 1/2000 dilution
Lane 1:
K562 whole cell lysate with PKA R2/PKR2 (pS99) phospho peptide
Lane 2:
K562 whole cell lysate with PKA R2/PKR2 non-phospho peptide
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 45 kDa
Observed band size: 51 kDa
false
Exposure time: 3min
- WB
Lab
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (AB32390)
All lanes:
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (ab32390) at 1/1000 dilution
Lane 1:
NIH/3T3 (Mouse embryonic fibroblast) whole cell lysates at 15 µg
Lane 2:
NIH/3T3 (Mouse embryonic fibroblast) treated with Calyculin A at 15 µg
Lane 3:
NIH/3T3 (Mouse embryonic fibroblast) treated with Calyculin A. Then the membrane was incubated with phosphatase at 15 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 45 kDa
Observed band size: 51 kDa
false
- WB
Lab
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (AB32390)
All lanes:
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (ab32390) at 1/1000 dilution
Lane 1:
Pig heart lysates at 15 µg
Lane 2:
Pig heart. Then the membrane was incubated with phosphatase at 15 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 45 kDa
Observed band size: 51 kDa
false
- WB
Lab
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (AB32390)
All lanes:
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (ab32390) at 1/1000 dilution
Lane 1:
C6 (Rat glial tumor glial cell) whole cell lysates at 15 µg
Lane 2:
C6 (Rat glial tumor glial cell) treated with 100ng/ml Calyculin A for 1 hour at 15 µg
Lane 3:
C6 (Rat glial tumor glial cell) treated with 100ng/ml Calyculin A for 1 hour.Then the membrane was incubated with phosphatase at 15 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 45 kDa
Observed band size: 51 kDa
false
- WB
CiteAb
Western blot - Anti-PKA R2/PKR2 (phospho S99) antibody [E151] (AB32390)
PKA R2/PKR2 (phospho S99) western blot using anti-PKA R2/PKR2 (phospho S99) antibody [E151] ab32390. Publication image and figure legend from Tang, Y., Shao, S., et al., 2019, Neural Plast, PubMed 31223308.
ab32390 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab32390 please see the product overview.
Effects of EA treatment on the expression levels of hippocampal APP, BACE1, and p-PKA in APP/PS1 mice using WB. (a) The effects of EA treatment on the relative expression of hippocampal APP in APP/PS1 mice. (b) The effects of EA treatment on the relative expression of hippocampal BACE1 in APP/PS1 mice. (c) The effects of EA treatment on the phosphorylation of PKA in the hippocampus of APP/PS1 mice. Data are presented as means ± SD; n = 7 per group. #p < 0.05 vs. the C group, ##p < 0.01 vs. the C group, and *p < 0.05 vs. the M group (C : control; M : model; EA : electroacupuncture).
false
Related conjugates and formulations (1)
-
Anti-PKA R2/PKR2 (phospho S99) antibody [E151] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
PKR2 regulates the activity of PKA by binding to the catalytic subunit in the absence of cAMP therefore inhibiting its activity. When cAMP is present it binds to the regulatory subunit PKR2 leading to the release and activation of the catalytic subunit of PKA. PKR2 is an integral part of the PKA holoenzyme complex which plays a critical role in mediating cellular responses to hormonal stimulation.
Pathways
PKR2 is heavily involved in the cAMP-dependent signaling pathway. This pathway is essential for translating extracellular signals into cellular actions. It interacts with various effector proteins including adenylate cyclases and phosphodiesterases to modulate responses such as gene transcription metabolism and memory formation. PKR2-related activity influences pathways shared with proteins like the G-protein subunits which facilitate the effects of neurotransmitters.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (52)
Recent publications for all applications. Explore the full list and refine your search
Scientific reports 15:27498 PubMed40721586
2025
Applications
Unspecified application
Species
Unspecified reactive species
Drug design, development and therapy 19:911-929 PubMed39959122
2025
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of biological chemistry 301:108183 PubMed39814226
2025
Applications
Unspecified application
Species
Unspecified reactive species
International journal of biological sciences 20:4532-4550 PubMed39247808
2024
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of neuroscience : the official journal of the Society for Neuroscience 44: PubMed39134419
2024
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of biological chemistry 300:107234 PubMed38552737
2024
Applications
Unspecified application
Species
Unspecified reactive species
iScience 26:107771 PubMed37731607
2023
Applications
Unspecified application
Species
Unspecified reactive species
PloS one 18:e0289133 PubMed37585373
2023
Applications
Unspecified application
Species
Unspecified reactive species
CNS neuroscience & therapeutics 30:e14362 PubMed37469037
2023
Applications
Unspecified application
Species
Unspecified reactive species
Pain 164:1718-1733 PubMed36727909
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com